ISRCTN84633360.

Study name	Permixon (R) 320 mg once a day open label treatment for patients participating in the placebo controlled study
Methods	Randomized controlled trial
Participants	Participant inclusion criteria: not available. However, condition of interest was benign prostatic hyperplasia.
Interventions	Permixon 320 mg once a day vs placebo
Outcomes	Primary outcome measure: not provided at time of registration Secondary outcome measures: not provided at time of registration
Starting date	Recruitment start date: 20 February 2000 Recruitment end date: 19 February 2004
Contact information	Mr T Terry University Hospitals of Leicester c/o Research and Development Office Leicester General Hospital NHS Trust Leicester LE1 4PW United Kingdom +44 (0)116 258 4109 research@lri.org.uk (contacted on 30 December 2022)
Notes